



Public Health Updates for Halton Physicians: Focus on Syphilis

Syphilis – Are you ready?

May 27, 2021











Agenda

- Syphilis is on the rise in Halton Dr. Joanna Oda, Associate Medical Officer of Health
 - Local context
- Keynote speaker Dr. Dale Kalina
 - Diagnosis
 - Treatment
 - Follow up

Question & Answer Session




T³ O¹ D³ O¹









Housekeeping











Use the Q&A function to ask, vote or comment on a question





Learning Objectives

By the end of this session, participants will be able to:

- Describe local Syphilis trends
- Follow the Canadian
 Guidelines on STIs for the
 diagnosis, treatment and
 follow up of Syphilis.

Overall series learning objective:

 By attending the Public Health **Updates for Halton Physicians** series, participants will be able to identify and discuss relevant and recent information about approaches to the prevention, diagnosis and management of key public health issues impacting their family medicine practice in both rural and urban settings.



Mitigating Potential Bias

All data, resources and recommendations presented are based on current scientific literature and data.











Disclosure of Financial Support

- This program is hosted and organized by Halton Region Public Health.
- I am a paid employee with Halton Region Public Health.

Potential for conflict(s) of interest:

 Halton Region Public Health receives funding from the Province of Ontario who also provides funding for public health research, programs and resources that may be discussed today.





Who diagnoses Syphilis



92%

of syphilis cases in Halton were tested and diagnosed by a private health care provider in 2020

8%
were tested
and diagnosed
by Public

Health










SyphilisTrends over time






Sources: Ontario Ministry of Health and Long-Term Care, Integrated Public Health System database, extracted by Public Health Ontario [May 6, 2021]. Population Estimates [2015-2017], IntelliHEALTH, Ontario Ministry of Health and Long-Term Care, extracted May 6, 2021. Population projections [2018-2020], IntelliHEALTH, Ontario Ministry of Health and Long-Term Care, Health Analytics Branch, extracted April 4, 2021. Excludes early congenital syphilis cases.








Number of cases, by sex
















Number of cases, by age



Source: Ontario Ministry of Health and Long-Term Care, Integrated Public Health System database, extracted by Public Health Ontario [May 6, 2021]. Excludes cases with unknown age










Age-adjusted trends, Halton and Ontario



Syphilis crude and age-standardized incidence rates (per 100,000), Halton residents compared to Ontario, 2010-



Sources: Halton and Ontario data: Ontario Ministry of Health and Long-Term Care, Integrated Public Health System database, extracted by Public Health Ontario [May 6, 2021]. Population Estimates [2010-2017], IntelliHEALTH, Ontario Ministry of Health and Long-Term Care, extracted May 6, 2021. Population projections [2018-2020], IntelliHEALTH, Ontario Ministry of Health and Long-Term Care, Health Analytics Branch, extracted April

4, 2021. Excludes cases with unknown age. Excludes early congenital syphilis cases







Benefits of diagnosing and treating Syphilis

For individuals

- Prevent symptoms and sequelae related to syphilis
- Decrease risk of HIV transmission and acquisition
- Decrease risk of late (tertiary) complications
- For communities
 - Reduce transmission to others including sexual transmission and mother-to-child
 - Screening and early diagnosis of contacts









First line Syphilis treatment for HCPs

- The preferred treatment for Syphilis is Bicillin LA - Penicillin G Benzathine, 2.4 million units
- Treatment has to be long acting (LA)
- HCPs can order from Halton Public Health
- halton.ca/physicians > Sexual Health **Clinics**
- Or call us at 905-825-6000 ext 4548



Health Department Promoting and Protecting Health

STI TREATMENT ORDER FORM Chlamydia/Gonorrhea/Syphilis

FAX this form to: 905-333-0971

Infection	Antibiotic	Dosage	Packaging	# doses requested	Lot # / Expiry date (to be corepleted by Public Health)
Chlamydia	Azithromcvin.	1 g PO	Azithromycin 250 mg x 4 tablets		
Gonorrhea	Ceftriaxone PLU\$ Azithromycin	250 mg IM PLU\$ 1 g PO	Ceftriaxone Sodium for injection BP 0.25 g vials, Lidocaine HCL[bj 1% USP 5 mL ampules (reconstitute with only 0.9 mL), PLUS Azithromycin 1g (as above)		
Syphilis	Penicillin G beozathine	2.4 mu IM Please see link to Canadian Caidelines on STIs for apphilis staging and douling	Penicillin G bearathine 1.2 mu x 2 Plus 21 gauge, 1.5" needle tips x 2		

Ordering Physician:				
Address:				
Phone:	Direct line:	Fax:		

For information on the treatment of Genorrhea search "genorrhea guidelines public health Ontario" or visit www.sublichealthe

For information on the Canadian guidelines on sexually transmitted infections search "Canadian guidelines on sexually transmitted











Syphilis – Public Health follow up

Open	Public Health receives positive lab report for syphilis and opens case investigation
	Public Health uses Ministry guidance to determine whether to initiate case management and sends a surveillance form to the testing HCP for completion
	Form provides details regarding risks, reason for testing, staging and treatment. This information is required by the Ministry to inform surveillance and by Public Health to inform case and contact management
	Public Health follows up with all cases of Infectious syphilis and their contacts to confirm treatment and partner notification
Close	PHU confirms that post treatment serology will be completed by testing HCP and closes case investigation





halton.ca (311

Dr. Dale Kalina, MD MBA FRCPC

Infectious Disease Physician

Medical Director Infection Prevention and Control – Joseph Brant Hospital





Dale R Kalina, MD MBA FRCPC
May 27 2021
Halton Public Health

QR Codes



Disclosures

- Faculty: McMaster University Division of Infectious Diseases
- Relationships with financial sponsors:
 - Speakers Bureau/Honoraria:
 - Burlington Dental Academy
 - Probus Club of Burlington
 - Gerrie Electric
 - No honoraria:
 - Rotary Club Burlington
 - CTV, CBC, Global, CHCH YourTV Halton
 - Consulting Fees: Appleby College, FaceDrive, Shaping Minds in Healthcare
 - Other:
 - Employee of Joseph Brant Hospital
 - Torstar Halton Community Advisory Committee

Disclosures


- I receive financial support from Joseph Brant Hospital and the Ministry of Health of Ontario in the form of salary and billing payments for patient services rendered.
- I have received in-kind support from Halton Public Health in the form of hosting the event

Potential for conflict(s) of interest:

• I have received no funding to support this presentation or to discuss any products (treatments or tests) for this presentation.

Mitigating Potential Bias

 All data presented is based on Health Canada recommendations and current literature resources




Epidemiology

- Increases in MSM
- Milder heterosexual increases
- Congenital syphilis reemerging from 2015

Risk Factors

- Unprotected sexual activity especially MSM
- Previous syphilis, HIV, or STBBI (STI)
- Born to someone diagnosed with syphilis in pregnancy
- Substance use, precarious housing

Clinical Manifestations



Primary










Secondary








Tertiary





















Screening and Diagnostic Tests

Traditional algorithm

Initial screen with NTT RPR	First TT TP-PA	Second TT FTA-ABS	Possible interpretation
Non-reactive	Non-reactive	Reactive	Primary syphilis with compatible history/clinical findings
Reactive (dilutions can vary)	Reactive	Reactive	 Syphilis, any stage * Previously treated syphilis
Non-Reactive	Reactive	Reactive	 Previously treated syphilis Early primary syphilis Late latent/tertiary syphilis
Reactive	Non-reactive	Non-reactive	False positive



Note: RPR titre ≥ 8 are more likely to be infectious syphilis.



Reverse algorithm

Reverse algorithm			
Initial screen with TT: EIA	NTT: RPR	Second TT: TP-PA, FTA-ABS or INNO-LA	Possible interpretation
Negative	Not done	Not done	Not a case. Repeat serology if at risk for syphilis
Borderline/ indeterminate	Non-reactive	Non-reactive or indeterminate	 Repeat serology as seroconversion may not have occurred yet (incubation period) If repeat serology remains unchanged, it is not a case of syphilis
Borderline/ indeterminate	Non-reactive	Reactive	 Early primary syphilis Late latent/tertiary syphilis Previously treated syphilis If laboratory does not do the confirmatory test, repeat serology to determine if the person is seroconverting If repeat serology remains unchanged it is not a case of syphilis
Positive	Reactive or non-reactive	Non-reactive	 False positive EIA without 2nd TT: Early primary syphilis Late latent/tertiary syphilis Previously treated syphilis
Positive	Reactive or non-reactive	Indeterminate	 Repeat serology to determine if it is early primary, late latent/tertiary or previously treated syphilis If repeat serology is unchanged this is likely to be a false positive EIA without 2nd TT: Syphilis, any stage, except with non-reactive NTT, then all but secondary stage Previously treated syphilis
Positive	Non-reactive	Reactive	Early primary syphilisLate latent/tertiary syphilisPreviously treated syphilis
Positive	Reactive	Reactive	 Syphilis, any stage * Previously treated syphilis



Alternate guides:

Source	QR
Public Health Agency of Canada	
Public Health Ontario	
Toronto Public Health	
<u>CJDIMM</u>	

Treatment

Stage	Preferred Treatment	Penicillin Allergy Treatment
Primary, Secondary, Early Latent	Benzathine Penicillin G 2.4M units x1	Doxycycline 100mg PO BID x 14d Ceftriaxone 1g IV/IM daily x 10d
Latent, Late Latent, Cardiovascular, and gumma	Benzathine Penicillin G 2.4M units IM weekly x 3 doses	Consider desensitization Doxycycline 100mg PO BID x 28d Ceftriaxone 1g IV/IM daily x 10d
All adult neurosyphilis	Aqueous Pen G 3-4M units IV Q4h x10-14d	Consider desensitization Ceftriaxone 2g IV/IM daily x 14d
Pregnancy	Treat as above according to stage	No alternative to Penicilin. Must desensitize
Congenital	Crystalline Penicillin G 50K units/kg x 10d (BID <1wk old, TID 1-4w old, QID >4w old)	N/A

Follow-Up

Adult




Congenital



Prevention & Control

Resources

- <u>UpToDate</u> (accessed last May 26, 2021)
- Public Health Agency of Canada (last accessed May 26, 2021)
- Bennett, Dolin, Blaser, Mandell, Douglas, and Bennett's Principles and Practice of Infectious Diseases Ninth Ed. Elsevier. 2019.
- <u>Canadian Pediatric Society</u> (Last accessed May 26 2021)





















Thank you!

doctors@halton.ca

halton.ca/physicians











